Phase III oncology clinical trial starts growth rate

Oncology trial starts declined overall by 4% between 2024 and 2025, although oncology trial starts increased in Phase II and in Phase III, respectively, by 3% and 4%.

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA

IQVIA Institute. (2025). Global R&D Trends 2026. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Via StatOrigin, https://statorigin.org/stat/stat_ZJSDXBSM2NV2EHJ65HCQC90RE4

Copy

MLA

IQVIA Institute. "Global R&D Trends 2026." 2025, https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_ZJSDXBSM2NV2EHJ65HCQC90RE4.

Copy

Chicago

IQVIA Institute. "Global R&D Trends 2026." 2025. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_ZJSDXBSM2NV2EHJ65HCQC90RE4.

Copy

BibTeX

@misc{iqvia2025phasec90re4, author = {{IQVIA Institute}}, title = {Global R\&D Trends 2026}, year = {2025}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_ZJSDXBSM2NV2EHJ65HCQC90RE4}, note = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/global-r-and-d-trends-2026. Accessed September 15, 2026.} }

Copy

Everything needed to check this number yourself, without taking our word for it.

Record last modified 17 September 2026. Value type: actual. Update cadence: annual. This page is permanently addressable at statorigin.org/stat/stat_ZJSDXBSM2NV2EHJ65HCQC90RE4.